Oncogenic signaling of class I PI3K isoforms

Oncogene

Volumn 27, Issue 18, 2008, Pages 2561-2574

  Denley, A ^a   Kang, S ^a,c   Karst, U ^a,b   Vogt, P K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b BCC 239 ^*  (Germany)

^c AMGEN INC   (United States)

Author keywords

Inhibitor; M EK; Oncogen ic transformation; PI3K; Ras; Signaling

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR FKHR;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; ENZYME ANALYSIS; GENE MUTATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHICK EMBRYO; CHICKENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FORKHEAD TRANSCRIPTION FACTORS; GLYCOGEN SYNTHASE KINASE 3; ISOENZYMES; MUTATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 42249098543     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210918     Document Type: Article

References (75)

1. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. (2004). Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431: 1007-1011.
2. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. (1998). The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 95: 14950-14955.
3. Aoki M, Blazek E, Vogt PK. (2001). A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 98: 136-141.
4. Aoki M, Jiang H, Vogt PK. (2004). Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA 101: 13613-13617. e-pub ahead of print: 1 September 2004.
5. Aoki M, Schetter C, Himly M, Batista O, Chang HW, Vogt PK. (2000). The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem 275: 6267-6275.
6. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. (2005). PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11: 933-935. e-pub ahead of print: 28 August 2005.
7. Bi L, Okabe I, Bernard DJ, Nussbaum RL. (2002). Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13: 169-172.
8. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. (1999). Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274: 10963-10968.
9. Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96: 7421-7426.
10. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B et al. (2006). A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25: 6648-6659.
11. Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT et al. (2003). Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 17: 1058-1067.
12. Bondeva T, Pirola L, Bulgarelli-Leva G, Rubio I, Wetzker R, Wymann MP. (1998). Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. Science 282: 293-296.
13. Bony C, Roche S, Shuichi U, Sasaki T, Crackower MA, Penninger J et al. (2001). A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca(2)+ oscillations in cardiac cells. J Cell Biol 152: 717-728.
14. Bos TJ, Monteclaro FS, Mitsunobu F, Ball Jr AR, Chang CH, Nishimura T et al. (1990). Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev 4: 1677-1687.
15. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. (2004). Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J 23: 2830-2840. e-pub ahead of print: 8 July 2004.
16. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
17. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS et al. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
18. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. (2005). Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11: 936-943.e-pub ahead of print: 28 August 2005.
19. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL et al. (2003). Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293.
20. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN et al. (1997). Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276: 1848-1850.
21. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB et al. (2005). Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65: 1961-1972.
22. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
23. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. (2006). A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349.
24. Fan QW, Weiss WA. (2006). Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 5: 2301-2305. e-pub ahead of print: 16 October 2006.
25. Grandage VL, Gale RE, Linch DC, Khwaja A. (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19: 586-594.
26. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
27. Gymnopoulos M, Elsliger MA, Vogt PK. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104: 5569-5574.e-pub ahead of print 21 March 2007.
28. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM et al. (2000). A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14: 783-794.
29. Hawkins PT, Anderson KE, Davidson K, Stephens LR. (2006). Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 34: 647-662.
30. Heo WD, Inoue T, Park WS, Kim ML, Park BO, Wandless TJ et al. (2006). PI(3,4,5)P3 and PI(4,5)P2 lipids target proteins with polybasic clusters to the plasma membrane. Science 314: 1458-1461. e-pub ahead of print: 9 November 2006.
31. Hickey FB, Cotter TG. (2006). BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J Biol Chem 281: 2441-2450. e-pub ahead of print: 16 November 2005.
32. Hooshmand-Rad R, Hajkova L, Klint P, Karlsson R, Vanhaesebroeck B, Claesson-Welsh L et al. (2000). The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. J Cell Sci 113: 207-214.
33. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE et al. (2005). PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507-514.e-pub ahead of print: 17 April 2005.
34. Kang S, Bader AG, Vogt PK. (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807. e-pub ahead of print: 12 January 2005.
35. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. (2006). Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103: 1289-1294. e-pub ahead of print: 23 January 2006.
36. Kawai S, Nishizawa M. (1984). New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol 4: 1172-1174.
37. Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N, Witte ON et al. (2004). Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103: 4268-4275. e-pub ahead of print: 19 February 2004.
38. Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. (2002). Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21: 5868-5876.
39. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-747. e-pub ahead of print: 27 April 2006.
40. Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. (2004). Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18: 1438-1440.
41. Leverrier Y, Okkenhaug K, Sawyer C, Bilancio A, Vanhaesebroeck B, Ridley AJ. (2003). Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem 278: 38437-38442. e-pub ahead of print: 16 July 2003.
42. Lyons JF, Wilhelm S, Hibner B, Bollag G. (2001). Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8: 219-225.
43. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. (2006). Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928.
44. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F et al. (2001). Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 25: 375-393.
45. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y et al. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317: 239-242.
46. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. (2003). Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17: 995-997.
47. Mulholland DJ, Dedhar S, Wu H, Nelson CC. (2006). PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25: 329-337.
48. Nalefski EA, Falke JJ. (1996). The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci 5: 2375-2390.
49. Newton AC, Johnson JE. (1998). Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1376: 155-172.
50. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. (2002). Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034. e-pub ahead of print: 18 July 2002.
51. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
52. Orme MH, Alrubaie S, Bradley GL, Walker CD, Leevers SJ. (2006). Input from Ras is required for maximal PI(3)K signalling in Drosophila. Nat Cell Biol 8: 1298-1302. e-pub ahead of print: 15 October 2006.
53. Rizo J, Sudhof TC. (1998). C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem 273: 15879-15882.
54. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
55. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. (2003). Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 170: 2647-2654.
56. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. e-pub ahead of print: 11 March 2004.
57. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. (2000). Function of PI3Kgamma in thymocyte development, T-cell activation, and neutrophil migration. Science 287: 1040-1046.
58. Seoane J, Le HV, Shen L, Anderson SA, Massague J. (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223.
59. Shaw M, Cohen P, Alessi DR. (1997). Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 416: 307-311.
60. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151-6161.
61. Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G et al. (1995). C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 55: 2275-2278.
62. Suire S, Condliffe AM, Ferguson GJ, Ellson CD, Guillou H, Davidson K et al. (2006). Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol 8: 1303-1309. e-pub ahead of print: 15 October 2006.
63. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. (2005). Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106: 1063-1066.
64. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058.
65. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204.
66. Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C et al. (1999). Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol 1: 69-71.
67. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC et al. (2001). Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70: 535-602.
68. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. (1997). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22: 267-272.
69. Vogt PK, Bader AG, Kang S. (2006). PI 3-kinases: hidden potentials revealed. Cell Cycle 5: 946-949. e-pub ahead of print: 1 May 2006.
70. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. (2000). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909-919.
71. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. (2003). Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 10: 207-213.
72. Ward SG, Finan P. (2003). Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3: 426-434.
73. Yip SC, El-Sibai M, Hill KM, Wu H, Fu Z, Condeelis JS et al. (2004). Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell Motil Cytoskeleton 59: 180-188.
74. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102: 18443-18448. e-pub ahead of print: 8 December 2005.
75. Zheng CF, Guan KL. (1994). Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. EMBO J 13: 1123-1131.